'Double negative' (CD4-, CD8-) TCR alpha beta+ adult T cell leukemia cells proliferated vigorously in the presence of IL-2 or IL-4.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

'Double negative' (CD4-, CD8-) TCR alpha beta+ adult T cell leukemia cells proliferated vigorously in the presence of IL-2 or IL-4.

Int Congr Ser; 956:137-40 1991. Unique Identifier : AIDSLINE ICDB/93688676
Hattori T; Sakai K; Suzushima H; Asou N; Takatsuki K; Matsuzaki Y; Nakauchi H; Natori H; Oizumi K; Second Dept. of Internal Medicine, Kumamoto Univ. Medical Sch.,; Japan

Abstract: Human T-cell leukemia virus type 1 (HTLV-1) is associated etiologically with adult T-cell leukemia (ATL). A distinctive feature of ATL cells is the universally expressed activated T-cell antigens, such as HLA-DR and CD25, with a phenotype of mature helper T cells (CD3+, CD4+, CD8-). The origins of ATL cells apparently are heterogeneous, because three cases of 'double-positive' (CD4+,CD8+) ATL cells have been reported. Recently, a case of 'double-negative' ATL cells was encountered, and the effects of various cytokines on these cells were observed. The ATL cells were CD4-,CD8-, but bore T-cell receptor alpha-beta product on their surfaces. Interleukin (IL)-1-beta and IL-7 induced a slight proliferation of ATL cells, whereas IL-3, IL-5 and IL-6 had not effect on proliferation. IL-2 and IL-4, in contrast, induced vigorous proliferation of ATL cells in a dose-dependent manner. Synergistic effects on the proliferation of these ATL cells by IL-1-beta, IL-3, and IL-7 with IL-2 were detected, but the synergism of IL-2 and IL-4 was minimal. This novel T-cell subset could be a target for HTLV-1-induced leukemia. Infection of the novel T-cell subset by HTLV-1 may alter or suppress the cellular immune responses of the gastrointestinal tract. (12 Refs)

Keywords: Antigens, CD3/ANALYSIS Antigens, CD4/*ANALYSIS Antigens, CD8/*ANALYSIS Cell Division/*DRUG EFFECTS Human Interleukin-2/*PHARMACOLOGY Interleukin-4/*PHARMACOLOGY Interleukins/PHARMACOLOGY Leukemia, T-Cell/*IMMUNOLOGY/PATHOLOGY Receptors, Antigen, T-Cell, alpha-beta/*ANALYSIS Receptors, Interleukin-2/ANALYSIS MONOGRAPH
930430
M9340833

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .